The Petitioners therefore request that the House of Commons urges the Secretary of State for Health to investigate why some Primary Care Trusts are not providing anti-TNF medicines for patients with ankylosing spondylitis.
On 28 May 2008, the National Institute for Health and Clinical Excellence (NICE) issued technology appraisal guidance recommending Adalimumab or etanercept (anti-TNF medications) as possible treatments for people with severe ankylosing spondylitis who:
have active spinal disease as assessed on two separate occasions 12 weeks apart; and
have tried at least two non-steroidal anti-inflammatory drugs (NSAIDs) but they have not worked.
All patients in England with ankylosing spondylitis, who meet the clinical requirements detailed in the published NICE guidance, should therefore be offered either Adalimumab or etanercept from 28 August 2008.